#ASH18: Bluebird and Celgene didn’t 'break' their next-gen BCMA CAR-T, so now they’ll double down on the dose and root for real durability
After the latest round of data on bb2121 from bluebird and Celgene left some of the more, um, demanding analysts disappointed in terms of durability, the ante has been raised substantially on the bet they’re making on their second-gen CAR-T — bb21217.
Designed to rely more on memory cells to amp up the efficacy — a perfectly reasonable theory that relies heavily on mouse data for its proof-of-concept rationale — bb21217 debuted its first data snapshot at ASH on Sunday.
Basic subscription required
Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.